Navigation Links
Landmark study defines benefits of early HIV testing and treatment for infected infants
Date:11/19/2008

regardless of their state of health. An NIAID study to identify the best drug regimen for these highly vulnerable children is under way.

"The new WHO guidelines will profoundly improve the survival rate and quality of life of infants born with HIV," says Ed Handelsman, M.D., chief of the Pediatric Medicine Branch in NIAID's Division of AIDS. "We are excited that we know the best time to begin treating HIV-infected infants; the challenge now for the global community is to ensure that all HIV-infected infants who need ART receive it soon enough."

The CHER study team, lead by Avy Violari, FCPaed, and Mark F. Cotton, MMed PhD, recruited and enrolled 377 infants between 6 and 12 weeks of age who had confirmed HIV infection but normal immune system development. Originally, the infants were randomly assigned to one of three regimens: start ART immediately and continue for 40 weeks; start ART immediately and continue for 96 weeks; or defer ART until signs of clinical or immunological progression to AIDS appeared. The ART regimen consists of ritonavir-boosted lopinavir, zidovudine and lamivudine, provided by GlaxoSmithKline PLC of Britain and the South African Department of Health. CHER is being conducted at two locations in South Africa: the Perinatal HIV Research Unit of the University of Witwatersrand; and the Children's Infectious Diseases Clinical Research Unit of Tygerberg Children's Hospital and Stellenbosch University. These sites are collaborating with the Medical Research Council Clinical Trials Unit in London.

In June 2007, a data and safety monitoring board (DSMB) overseeing CHER found that the babies who received immediate ART were four times less likely to die than the babies whose treatment was deferred. This was true even though 66 percent of those in the deferred treatment arm had met the criteria for ART during the first 32 weeks of the trial and already had begun treatment. Consequently, the DSMB recommended, and NIAID agreed, t
'/>"/>

Contact: Laura Sivitz
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
2. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
3. Pathway to cell death redefined in landmark study
4. Pathway to cell death redefined in landmark study
5. UCLA to lead local study center in landmark government study of child health
6. Landmark Report: Excess Body Fat Causes Cancer
7. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
8. Landmark trial to evaluate cardioprotective properties of insulin
9. Safeway Inc. and the Prostate Cancer Foundation to Fund Landmark Prostate Cancer Research Collaboration
10. Yale launches landmark VIRGO study of young women with heart disease
11. Hospital Launches Landmark Project in Emergency Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Chicago, IL (PRWEB) August 28, 2014 ... IT Supplement shows that while most hospitals utilize a ... of health care information technology is still a challenge. ... in the August issue of Health Affairs , ... Health Forum’s Health Care Data Center, as well as ...
(Date:8/28/2014)... The New England Journal of Medicine ... trial of a drug shown to safely reduce the ... intranasally infected with respiratory syncytial virus (RSV). ... Tennessee Health Science Center researcher Infectious Disease Specialist John ... , RSV is the most common cause of ...
(Date:8/28/2014)... change is hurting reproduction of the endangered Devils Hole pupfish, ... as few as 35 individuals, new research by the University ... report that geothermal water on a small shelf near the ... the pupfish live is heating up as a result of ... levels. , The hotter water, which now reaches more ...
(Date:8/28/2014)... smoking kills approximately 440,000 Americans each year, according ... It,s the leading cause of preventable death worldwide. ... resort to nicotine replacement therapies. , A ... University of Miami (UM) suggest that small dosages ... harmful to human musculoskeletal system, due to overuse. ...
(Date:8/28/2014)... August 28, 2014 Dr. Paul Kovatis is ... of the U.S. military for his efforts to treat many ... Wounded Warriors Foundation and several other military organizations. Dr. ... Tiger in WWII. Having five members of his immediate ... National Cemetery, it’s no wonder Dr. Kovatis is so dedicated ...
Breaking Medicine News(10 mins):Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:DeVincenzo study breakthrough in RSV research 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 3Health News:Are cigarette substitutes a safe alternative? It depends on user habits 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis 2
... HOUSTON, Feb. 2, 2009 Stuart Dryer, the John and ... chair at the University of Houston, has been awarded the ... of Science (AAAS). AAAS is the world,s ... have made distinguished contributions to the advancement of science. ...
... Feb. 2, 2010 News media and others interested ... next in a series of American Chemical Society (ACS) ... variety of pertinent career topics impacting science and engineering ... p.m. Eastern Time, the free webinar will feature Carolyn ...
... that tension on DNA molecules can affect gene expression---the process ... what to do. Scientists understand the chemistry involved ... The U-M group is believed to be the first to ... Their paper is published in the current edition of ...
... Government ... in which he will oversee all of the publisher’s editorial and commercial operations. , ... Washington, DC (PRWEB) Feb. 4, 2010 ... General Manager, a role in which he will oversee all of the publisher’s editorial and ...
... ... to Stay Awake and Alert , ... Jackson, CA (PRWEB) February 2, 2010 -- 5150 Juice (5150juice.com) today announced a handy ... up to 500mgs per ounce of caffeine to turn any drink into a Super Energy ...
... Former ... StatCom in a strategic partnership program that helps hospitals transform throughput operations. , ... Atlanta, GA (PRWEB) February ... MBA, to the StatCom transformation team as enterprise vice president, Western region. Previously, Thalken ...
Cached Medicine News:Health News:Biology professor becomes 5th at UH to reach prestigious AAAS status 2Health News:ACS webinar features tips for finding and building a career in the food and flavor industries 2Health News:Mechanical forces could affect gene expression 2Health News:Government Executive Media Group Completes Leadership Search 2Health News:Government Executive Media Group Completes Leadership Search 3Health News:5150 Juice Launches Pocket-Sized Syringe Containing 166.6mg of Liquid Caffeine for Consumers to Add To Their Favorite Drink 2Health News:5150 Juice Launches Pocket-Sized Syringe Containing 166.6mg of Liquid Caffeine for Consumers to Add To Their Favorite Drink 3Health News:Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region 2Health News:Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region 3
(Date:8/28/2014)... Aug. 28, 2014  In recognition of the increased ... from the flu, pneumonia, shingles and other illnesses, ... declared September to be Senior Vaccination Month. Because ... is important that adults ages 65 years and ... CVS pharmacists and MinuteClinic nurse practitioners and physician ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. ... company that merged with MabVax Therapeutics, Inc. on ... significant progress related to the development of its ... was recovered using the Company,s internally developed antibody ... potential for multiple antibody based therapeutic and diagnostic ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: